Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MOREWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MOREUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don’t find the answers you’re looking for, contact us for additional assistance.
EXPLORE MOREThis gene is a member of the MAGEA gene family. The members of this family encode proteins with 50 to 80% sequence identity to each other. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. The MAGEA genes are clustered at chromosomal location Xq28. They have been implicated in some hereditary disorders, such as dyskeratosis congenita.
Loading...| CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | HLA | Vector Type | Inquiry & Datasheet |
| TCR-L060 | Murinized (from Human) anti-MAGEA3 (KKLLTQHFVQENYLEY) T Cell Receptor, pMSGV1 | Human | Murinized (from Human) | KKLLTQHFVQENYLEY | HLA-A2 | retroviral vector | ||
| TCR-L061 | Mouse anti-MAGEA3 (EVDPIGHLY) T Cell Receptor, pLXSN | Human | Mouse | EVDPIGHLY | HLA-A1 | retroviral vector | ||
| TCR-L062 | Human anti-MAGEA3 (EVDPIGHLY) T Cell Receptor, pMSGV1 | Human | Human | EVDPIGHLY | HLA-A1 | retroviral vector | ||
| TCR-L059Z | Murinized anti-MAGEA3 (aa243-258) T cell receptor, pCDTCR1 | Human | Murinized (from Human) | KKLLTQHFVQENYLEY | HLA-A2 | Lentiviral | ||
| TCR-L060Z | Mouse anti-MAGEA3 (aa168-176) T cell receptor (Affinity enhanced), pCDTCR1 | Human | Mouse | EVDPIGHLY | HLA-A1 | Lentiviral | ||
| TCR-L061Z | Human anti-MAGEA3 (aa168-176) T cell receptor, pCDTCR1 | Human | Human | EVDPIGHLY | HLA-A1 | Lentiviral | ||
| TCR-C119Z | Human anti-MAGE-A3 T cell receptor (MAG-IC3), pCDTCR1 | Human | MAG-IC3 | Human | EVDPIGHLY | HLA-A1 | Lentiviral | |
| TCR-C120Z | Mouse anti-MAGE-A3 T cell receptor, pCDTCR1 | Human | Mouse | KVAELVHFL | HLA-A*0201 | Lentiviral | ||
| TCR-C121Z | Mouse anti-MAGE-A3 (FLWGPRALV) T cell receptor, pCDTCR1 | Human | Mouse | FLWGPRALV | HLA-A*0201 | Lentiviral | ||
| TCR-C122Z | Mouse anti-MAGE-A3 (KVAELVHFL) T cell receptor (Affinity enhanced), pCDTCR1 | Human | Mouse | KVAELVHFL | HLA-A*0201 | Lentiviral | ||
| TCR-C123Z | Human anti-MAGE-A3 T cell receptor (A10), pCDTCR1 | Human | A10 | Human | aa 168-176 | HLA-A*01 | Lentiviral | |
| TCR-C124Z | Human anti-MAGE-A3 T cell receptor (13-18), pCDTCR1 | Human | 13-18 | Human | aa 168-176 | HLA-A*01 | Lentiviral | |
| TCR-C125Z | Human anti-MAGE-A3 (EVDPIGHLY) T cell receptor (Affinity enhanced), pCDTCR1 | Human | Human | EVDPIGHLY | HLA-A*01 | Lentiviral | ||
| TCR-C126Z | Human anti-MAGE-A3 T cell receptor (6F9), pCDTCR1 | Human | 6F9 | Human | QHFVQENYLEY | HLA-DPB1*04:01 | Lentiviral | |
| TCR-C127Z | Human anti-MAGE-A3 T cell receptor (R12C9), pCDTCR1 | Human | R12C9 | Human | QHFVQENYLEY | HLA-DPB1*04:01 | Lentiviral | |
| TCR-C128Z | Human anti-MAGE-A3 T cell receptor (ESBI 648), pCDTCR1 | Human | ESBI 648 | Human | aa 167-176 | HLA-A1 | Lentiviral | |
| TCR-C129Z | Human anti-MAGE-A3 T cell receptor (TCRVα38/Vβ2), pCDTCR1 | Human | TCRVα38/Vβ2 | Human | KKLLTQHFVQENYLEY | HLA-DP4 | Lentiviral | |
| TCR-C130Z | Human anti-MAGE-A3 T cell receptor (TCRVα3/Vβ28), pCDTCR1 | Human | TCRVα3/Vβ28 | Human | ALKVDVEERV | HLA-A2 | Lentiviral | |
| TCR-L245 | Human anti-MAGE-A3 T cell receptor, pCDTCR1 | Human | Human | KVAELVHFL | HLA-A*0201 | Lentiviral | ||
| TCR-L246 | Human anti-MAGE-A3 T cell receptor, pCDTCR1 | Human | Human | FLWGPRALV | HLA-A*0201 | Lentiviral | ||
| TCR-L359 | Human anti-MAGE-A3 T cell receptor (EB81-103), pCDTCR1 | Human | EB81-103 | Human | EVDPIGHLY | HLA-A1 | Lentiviral | |
| TCR-L362 | Murinized anti-MAGE-A3 T cell receptor (6F9), pCDTCR1 | Human | 6F9 | Murinized | AA243-258 | HLA-DP*0401 | Lentiviral | |
| TCR-L363 | Murinized anti-MAGE-A3 T cell receptor (R12C9), pCDTCR1 | Human | R12C9 | Murinized | AA243-258 | HLA-DP*0401 | Lentiviral |
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.
LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.
LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.
LEARN MORE
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE
